Stage 0 Chronic Lymphocytic Leukemia
Current Clinical Trials
Note: Some citations in the text of this section are followed by a level of
evidence. The PDQ editorial boards use a formal ranking system to help the
reader judge the strength of evidence linked to the reported results of a
therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence for more
information.)
Because of the indolent nature of stage 0 chronic lymphocytic leukemia,
treatment is not indicated.[1] The French Cooperative Group on Chronic
Lymphocytic Leukemia randomized 1,535 patients with previously untreated stage A
disease to receive either chlorambucil or no immediate treatment and found no
survival advantage for immediate treatment with chlorambucil.[2][Level of evidence: 1iiA] A meta-analysis of six trials of immediate versus deferred
therapy with chlorambucil (including the aforementioned trial by the French
Cooperative Group) showed no difference in overall survival at 10
years.[3][Level of evidence: 1iiA] Whether immediate therapy with the
nucleoside analogs or other newer strategies will be superior to a watchful
waiting approach is uncertain.
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage 0 chronic lymphocytic leukemia. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Casper JT: Prognostic features of early chronic lymphocytic leukaemia. International Workshop on CLL. Lancet 2 (8669): 968-9, 1989.
-
Dighiero G, Maloum K, Desablens B, et al.: Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 338 (21): 1506-14, 1998.
[PUBMED Abstract]
-
Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 91 (10): 861-8, 1999.
[PUBMED Abstract]
Back to Top
< Previous Section | Next Section > |